You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

CLADRIBINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Cladribine

A generic version of CLADRIBINE was approved as cladribine by HIKMA on February 28th, 2000.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CLADRIBINE?
  • What are the global sales for CLADRIBINE?
  • What is Average Wholesale Price for CLADRIBINE?
Drug patent expirations by year for CLADRIBINE
Drug Prices for CLADRIBINE

See drug prices for CLADRIBINE

Recent Clinical Trials for CLADRIBINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 2
University of FloridaPhase 2
Northern Jiangsu Province People's HospitalPhase 2

See all CLADRIBINE clinical trials

Pharmacology for CLADRIBINE
Medical Subject Heading (MeSH) Categories for CLADRIBINE
Paragraph IV (Patent) Challenges for CLADRIBINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MAVENCLAD Tablets cladribine 10 mg 022561 1 2022-04-07

US Patents and Regulatory Information for CLADRIBINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa CLADRIBINE cladribine INJECTABLE;INJECTION 076571-001 Apr 22, 2004 AP RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience CLADRIBINE cladribine INJECTABLE;INJECTION 200510-001 Oct 6, 2011 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma CLADRIBINE cladribine INJECTABLE;INJECTION 075405-001 Feb 28, 2000 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hisun Pharm Hangzhou CLADRIBINE cladribine INJECTABLE;INJECTION 210856-001 Nov 25, 2019 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for CLADRIBINE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Merck Europe B.V. Mavenclad cladribine EMEA/H/C/004230
Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.
Authorised no no no 2017-08-22
Lipomed GmbH Litak cladribine EMEA/H/C/000504
Litak is indicated for the treatment of hairy-cell leukaemia.
Authorised no no no 2004-04-14
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.